Molecular imaging and advanced MRI findings following immunotherapy in patients with brain tumors

Expert Rev Anticancer Ther. 2020 Jan;20(1):9-15. doi: 10.1080/14737140.2020.1705788. Epub 2019 Dec 23.

Abstract

Introduction: Currently, immunotherapy using vaccination strategies or oncolytic virus approaches, cell-based immunotherapy, and the blockade of immune checkpoints are under evaluation in patients with brain cancer. Here we summarize clinically significant imaging findings such as treatment-related changes detected by advanced neuroimaging techniques following the most suitable immunotherapy options currently used in neuro-oncology. We, furthermore, provide an overview of how these advanced imaging techniques may help to overcome shortcomings of standard MRI in the assessment and follow-up of patients with brain cancer.Areas covered: The current literature on neuroimaging for immunotherapy in the field of brain tumors, with a focus on gliomas and brain metastases is summarized.Expert commentary: Data suggest that imaging parameters primarily derived from amino acid PET, diffusion- and perfusion-weighted MRI, or MR spectroscopy are particularly helpful for the evaluation of treatment response and provide valuable information for the differentiation of treatment-induced changes from actual brain tumor progression following various immunotherapy approaches.

Keywords: CAR-T cells; FET PET; checkpoint inhibitors; dendritic cells; oncolytic virus immunotherapy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Brain Neoplasms / diagnostic imaging
  • Brain Neoplasms / pathology
  • Brain Neoplasms / therapy*
  • Disease Progression
  • Drug Resistance, Neoplasm
  • Glioma / diagnostic imaging
  • Glioma / pathology
  • Glioma / therapy*
  • Humans
  • Immunotherapy / methods*
  • Magnetic Resonance Imaging / methods
  • Molecular Imaging
  • Neoplasm Recurrence, Local